SNSS Financial Facts

Research and development: 6.21M
Net loss: -10.09M
See Full Income Statement

Total assets: 40.73M
Cash and cash equivalents: 23.86M
See Full Balance Sheet

Sunesis Pharmaceuticals Inc. (SNSS) Earnings

  |   Expand Research on SNSS
Next EPS Date 8/1/16 *Est. EPS Growth Rate +7.7% *Last Qtr.
Average EPS % Beat Rate +4.4% Revenue Growth Rate -29.7% *Last Qtr.
Average % Move 1-Wk after EPS 0.0% Normal Earnings Time Before Open
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. 1-Week % 1-Day % Details
5/5/16 Q116 -$0.12-$0.12 $0.00$600K$1K N/A Details
3/10/16 Q415 -$0.15-$0.14 -$0.01$670K$700K N/A Details
11/5/15 Q315 -$0.09-$0.15 +$0.06$700K$1.09M N/A Details
7/30/15 Q215 -$0.15-$0.13 -$0.02$854K$1.21M N/A Details
5/5/15 Q115 -$0.13-$0.16 +$0.03$854K$980K N/A Details
3/12/15 Q414 -$0.02-$0.19 +$0.17$896K$1.17M N/A Details
11/10/14 Q314 -$0.25-$0.17 -$0.08$854K$1.97M N/A Details
8/5/14 Q214 -$0.20-$0.17 -$0.03$2M$1.32M N/A Details